Abstract
The COVID-19 pandemic has posed significant challenges to public health systems worldwide, necessitating accurate and adaptable forecasting models to manage and mitigate its impacts. This study presents a novel forecasting framework based on a Machine Learning-enabled Susceptible-Infected-Recovered (ML-SIR) model with time-varying parameters to predict COVID-19 dynamics across multiple geographies. The model incorporates emergent patterns from reported time-series data to estimate new hospitalisations, hospitalised patients, and new deaths. Our framework adapts to the evolving nature of the pandemic by dynamically adjusting the infection rate parameter over time and using a Fourier series to capture oscillating patterns in the data. This approach improves upon traditional SIR and forecasting models, which often fail to account for the complex and shifting dynamics of COVID-19 due to new variants, changing public health interventions, and varying levels of immunity. Validation of the model was conducted using historical data from the United States, Italy, the United Kingdom, Canada, and Japan. The model’s performance was evaluated based on the Mean Absolute Percentage Error (MAPE) and Absolute Percentage Error of Cumulative values (CAPE) for three-month forecast horizons. Results indicated that the model achieved an average MAPE of 32.5% for new hospitalisations, 34.4% for patients, and 34.8% for new deaths, for three-month forecasts. Notably, the model demonstrated superior accuracy compared to existing forecasting models with like-for-like disease metrics, countries and forecast horizons. The proposed ML-SIR model offers a robust and adaptable tool for forecasting COVID-19 dynamics, capable of adjusting to new time-series data and varying geographical contexts. This adaptability makes it suitable for localised hospital capacity planning, scenario modelling, and for application to other respiratory infectious diseases with similar transmission dynamics, such as influenza and RSV. By providing reliable forecasts, the model supports informed public health decision-making and resource allocation, enhancing preparedness and response efforts.
Competing Interest Statement
All authors are current or previous employees of Airfinity Ltd.
Funding Statement
This study did not receive any external funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://data.who.int/dashboards/covid19/
https://ourworldindata.org/coronavirus
https://data.cdc.gov/Case-Surveillance/COVID-19-Case-Surveillance-Public-Use-Data-with-Ge/n8mc-b4w4/about_data
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
